Trial Profile
Open extension study evaluating the long term efficacy, safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed the previous ziprasidone study A1281031.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2021
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Pfizer; Viatris
- 22 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 24 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.